Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial (Q38135798)

1 October 2017

Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial (English)

1 reference

metastatic renal cell carcinoma

1 October 2017

phase III clinical trial

0 references

1 reference

1 reference

1 reference

1

Robert J Motzer

1 reference

1 October 2017

15

David Cella

1 reference

1 October 2017

14

Cezary Szczylik

1 reference

1 October 2017

Dmitry Nosov

2

1 reference

1 October 2017

Timothy Eisen

3

1 reference

1 October 2017

Igor Bondarenko

4

1 reference

1 October 2017

Vladimir Lesovoy

5

1 reference

1 October 2017

Oleg Lipatov

6

1 reference

1 October 2017

Piotr Tomczak

7

1 reference

1 October 2017

Oleksiy Lyulko

8

1 reference

1 October 2017

Anna Alyasova

9

1 reference

1 October 2017

Mihai Harza

10

1 reference

1 October 2017

Mikhail Kogan

11

1 reference

1 October 2017

Boris Y Alekseev

12

1 reference

1 October 2017

Cora N Sternberg

13

1 reference

1 October 2017

Cristina Ivanescu

16

1 reference

1 October 2017

Andrew Krivoshik

17

1 reference

1 October 2017

Andrew Strahs

18

1 reference

1 October 2017

Brooke Esteves

19

1 reference

1 October 2017

Anna Berkenblit

20

1 reference

1 October 2017

Thomas E Hutson

21

1 reference

1 October 2017

language of work or name

English

0 references

publication date

9 September 2013

1 reference

Journal of Clinical Oncology

1 October 2017

1 reference

1 October 2017

31

1 reference

1 October 2017

30

1 reference

1 October 2017

3791-3799

1 reference

AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5569677

Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5569677

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5569677

Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5569677

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5569677

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5569677

Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5569677

Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5569677

Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5569677

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5569677

Metastatic renal cell carcinoma: many treatment options, one patient

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5569677

Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5569677

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5569677

Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5569677

Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5569677

Development and validation of a scale to measure disease-related symptoms of kidney cancer

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5569677

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5569677

Sorafenib in advanced clear-cell renal-cell carcinoma

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5569677

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5569677

KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties.

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5569677

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5569677

The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5569677

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5569677

EuroQol--a new facility for the measurement of health-related quality of life

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5569677

Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5569677

Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5569677

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5569677

Combining distribution- and anchor-based approaches to determine minimally important differences: the FACIT experience

31 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24019545

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24019545

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1200/JCO.2012.47.4940

1 reference

1 October 2017

1 reference

1 October 2017

1 reference